In the last couple weeks, we’ve compared the potential impact of using one-size-fits-all standards of care instead of personalized treatment plans for patients with breast cancer and colon cancer. In both case studies, the patients’ quality of life and long-term prognosis were compromised when decisions were made on an average rather than on the individual.
The share of consumers in a high deductible plan increased from 36 percent to 49 percent among those who purchase their own insurance, according to a new Kaiser Family Foundation poll released today. This poll found the rise in deductibles was accompanied by an increase in the share of enrollees who rate their coverage as “not so good” or “poor” from 20 percent in 2014 and 21 percent in 2015 to 31 percent in 2016.
In a final rule released late last week, the Department of Health and Human Services’ Office of Civil Rights declined to provide details on health insurance benefit designs it considers to be discriminatory. This is understandably disappointing to patients who have found many of the plans offered in the new health insurance marketplaces appear to be designed to discourage enrollment by individuals with certain health conditions.
In the age of personalized medicine, biomarkers (short for “biological markers”) are emerging as important tools in drug development. A biomarker is a measure or physical sign that can be used to determine how the body is functioning. This can help researchers develop more individualized treatments, provide an early warning sign for certain health risks and accelerate patient access to certain therapies.
Last week the Alliance for Integrity and Reform of 340B (AIR340B)—of which PhRMA is a member—released a new report looking at charity care provided by 340B hospitals. This expands on previous research on the topic conducted in 2014. Even since implementation of the Affordable Care Act, 64 percent of 340B hospitals are providing less charity care than the national average for all hospitals, including for-profit hospitals. This is even as 340B hospitals receive steep discounts on medicines.
At PhRMA, we have the honor of highlighting the hope that America’s biopharmaceutical companies bring to patients in the form of innovative treatments and cures. But beyond the value that medicines deliver to patients is the profound impact a strong biopharmaceutical sector has on our local, state and national economies.
The economic impact of the biopharmaceutical sector is detailed in a new report that was prepared for PhRMA by TEConomy Partners, LLC and which highlights how the discovery, development and delivery of innovative medicines translate into high-wage jobs, substantial tax revenue and growing economic output in our local communities.
For low-income seniors managing multiple chronic conditions, medical expenses can add up. That’s where the Medicare Part D Extra Help program can make a big difference.
As we saw with hypothetical Medicare patient Diane, the Extra Help program provides the assistance she needs to access her medications and remain adherent while helping her avoid costly hospitalizations. Today, we’re sharing Mateo’s story. Mateo is also a hypothetical Medicare patient benefitting from the Extra Help Program.
As the U. S. health care market continues to shift toward a system that prioritizes and rewards value, there is increasing attention on the development and use of value assessment frameworks. When well-structured and used appropriately, frameworks to assess the value of medical tests, treatments and health care services can be useful in the private market to support patient-centered health care. However, as the number of emerging value frameworks continues to grow, we are seeing great variability in the methods and approaches being used, as well as significant issues related to the process through which frameworks are developed.
For more than 30 years, the U.S. biopharmaceutical industry has been the world leader in the development of new medicines, driving innovation for patients. And PhRMA member companies continue to be at the forefront.
According to the 2016 Biopharmaceutical Research Industry Profile and corresponding industry chart pack, Biopharmaceuticals In Perspective, released today, PhRMA member companies invested an estimated $58.8 billion in research and development (R&D) in 2015, up 10.3 percent from 2014.
A dynamic and collaborative health care ecosystem is crucial to conducting efficient and effective clinical trials, but two-thirds of trials fail to enroll enough participants. Misconceptions and a lack of awareness about this important research often keep people from participating. That’s why we recognized Clinical Trials Awareness Week – to shine a spotlight on the unsung heroes of clinical trials, including patients and researchers, like Nina and Abbe, who each shared their take on the clinical trial process with us.
Topics: Clinical Trials